Results 11 to 20 of about 91,972 (285)

Myasthenia gravis [PDF]

Nature Reviews Disease Primers, 2019
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Patients are grouped according to the presence
Gilhus, Nils Erik, Tzartos, Socrates, Evoli, Amelia, Palace, Jacqueline, Burns, Ted M, Verschuuren, Jan J G M   +5 more
semanticscholar   +10 more sources

MYASTHENIA GRAVIS. [PDF]

JAMA: The Journal of the American Medical Association, 1906
n ...
C. EUGENE RIGGS
openalex   +4 more sources

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis [PDF]

Muscle and Nerve, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN,
Andersen, Henning, Barohn, Richard J, Benatar, Michael, Burns, Ted M, Casasnovas, Carlos, De Bleecker, Jan, Fujita, Kenji P, Howard, James F, Jr., Illa, Isabel, Jacob, Saiju, Kissel, John T, Mantegazza, Renato, Muppidi, Srikanth, Murai, Hiroyuki, Nowak, Richard J, O'Brien, Fanny L, Utsugisawa, Kimiaki, Vissing, John, Vu, Tuan H, Wang, Jing Jing   +19 more
core   +3 more sources

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Annals of Clinical and Translational Neurology, 2020
Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
Renato Mantegazza, Fanny L. O'Brien, Marcus Yountz, James F. Howard Jr, for the REGAIN study group   +4 more
doaj   +2 more sources

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

BMJ Open, 2020
Objectives To approximate the rate of familial myasthenia gravis and the coexistence of other autoimmune disorders in the patients and their families.Design Retrospective cohort study.Setting Clinics across North America.Participants The study included ...
Joel Oger, Joshua D Green, Bryan J Traynor, Richard J Barohn, Michael Benatar, Emanuela Bartoccion, Derrick Blackmore, Vinay Chaudhry, Manisha Chopra, Andrea Corse, Mazen M Dimachkie, Amelia Evoli, Julaine Florence, Miriam Freimer, James F Howard, Theresa Jiwa, Henry J Kaminski, John T Kissel, Wilma J Koopman, Bernadette Lipscomb, Michelanglo Maestri, Mariapaola Marino, Janice M Massey, April McVey, Michelle M Mezei, Srikanth Muppidi, Michael W Nicolle, Robert M Pascuzzi, Mamatha Pasnoor, Alan Pestronk, Carlo Provenzano, Roberta Ricciardi, David P Richman, Julie Rowin, Donald B Sanders, Zaeem Siddiqi, Aimee Soloway, Gil I Wolfe, Charlie Wulf, Daniel B Drachman   +39 more
doaj   +2 more sources

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Journal of Neurology, 2023
Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
A. Meisel, D. Annane, T. Vu, R. Mantegazza, M. Katsuno, R. Aguzzi, G. Frick, L. Gault, J. Howard   +8 more
semanticscholar   +1 more source

Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations

Journal of Clinical Medicine, 2021
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 ...
L. Dresser, R. Wlodarski, K. Rezania, B. Soliven   +3 more
semanticscholar   +1 more source

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

JAMA Neurology, 2022
This randomized clinical trial investigates the efficacy and safety of rituximab compared vs placebo as an add-on with standard of care for myasthenia gravis.
F. Piehl, Ann Eriksson-Dufva, A. Budzianowska, Amalia Feresiadou, William Hansson, M. A. Hietala, I. Håkansson, Rune Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. Punga, R. Press, K. Samuelsson, P. Sundström, O. Wickberg, S. Brauner, T. Frisell   +20 more
semanticscholar   +1 more source

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study

Proceedings of the National Academy of Sciences of the United States of America, 2022
Significance Our study, involving 1,873 patients and 36,370 healthy individuals, is an extensive genome-wide study of myasthenia gravis. Our genome-wide association and transcriptome-wide association analyses identified two signals, namely CHRNA1 and ...
Ruth Chia, S. Sáez-Atienzar, N. Murphy, A. Chiò, C. Blauwendraat, R. Roda, P. Tienari, H. Kaminski, R. Ricciardi, M. Guida, A. De Rosa, L. Petrucci, A. Evoli, C. Provenzano, D. Drachman, B. Traynor   +15 more
semanticscholar   +1 more source

Current Treatment of Myasthenia Gravis

Journal of Clinical Medicine, 2022
Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with
Mohammed K Alhaidar, Sumayyah K Abumurad, B. Soliven, K. Rezania   +3 more
semanticscholar   +1 more source